Company news

Korro Bio, Inc. news in 2026

Korro Bio, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update

November 5, 2026

Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency

October 22, 2026

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 16, 2026

Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121

October 5, 2026

Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 6, 2026

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 10, 2026

Korro to Present at the 2026 Jefferies Global Healthcare Conference

May 26, 2026

Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency

May 20, 2026

Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 18, 2026

Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 7, 2026

Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences

April 16, 2026

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 10, 2026

Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 12, 2026

Korro Announces Oversubscribed $85 Million Private Placement

March 9, 2026

Korro to Present at the TD Cowen 46th Annual Health Care Conference

February 25, 2026

Korro to Host Virtual Analyst Day on January 27, 2026

January 20, 2026

Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 8, 2026

Decks in 2026